Abilify Review Shows FDA Debate Over QTc Methods Of Analysis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s review of Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify suggests that the method of analysis used to detect QT prolongation is key to the results.